GLP-1 for Adolescent PCOS: What the 2025 TEAL Trial Showed

Adolescent polycystic ovary syndrome is one of the most under-served corners of women's health. The diagnostic criteria are more conservative than the adult criteria for good reasons, but the phenotype — irregular cycles, hyperandrogenism, weight gain that resists lifestyle intervention, insulin resistance that drifts toward prediabetes — is recognizable in many teenagers. By the time these patients reach adult care, the metabolic profile is often already entrenched. Most clinics will not prescribe GLP-1 to teens or young adults with PCOS. Many will not even discuss it.

The 2025 TEAL Study changed that conversation. Morelli, Cree, and colleagues at the University of Colorado Anschutz Medical Campus ran a phase 3, randomized, open-label trial of oral semaglutide versus a standardized lifestyle intervention in adolescent females with obesity and polycystic ovary syndrome. The result at four months: a mean body-weight change of −5.8% in the semaglutide arm versus −1.9% in the lifestyle arm. The PCOS-specific secondary endpoints — insulin markers, androgen profile, cycle data — were collected as part of the protocol.

This post walks through what TEAL showed, why the adolescent window matters, how the case for and against early intervention is structured, the contraception question that dominates the practical conversation, and how the TelePeptide protocol handles adolescent and young-adult patients.

Why adolescent PCOS is different

PCOS in an adult is a well-characterized clinical picture. The Rotterdam criteria — two of three from irregular cycles, hyperandrogenism, and polycystic ovarian morphology — work well for women in their twenties and beyond. The cycle has been established for years. The androgen-driven phenotype is consolidated. The metabolic profile is stable enough to characterize.

Adolescent PCOS is harder. Cycle irregularity in the first two years after menarche is common and often physiological — the hypothalamic-pituitary-ovarian axis is still maturing, and many anovulatory cycles during this period are not pathological. Polycystic ovarian morphology on ultrasound is essentially uninformative in adolescents — the multifollicular pattern is too common in the general adolescent population to discriminate. The international guidelines (including the 2023 International PCOS Guideline) explicitly use a more conservative diagnostic framework for adolescents: persistent irregular cycles beyond the early post-menarcheal window plus clinical or biochemical hyperandrogenism. Ultrasound is not used.

This conservative diagnostic approach is appropriate — it prevents over-diagnosis of normal pubertal variation. But it also means that adolescents with clear emerging PCOS phenotype often have to wait several years for a formal diagnosis, during which time the metabolic and androgen-driven features can entrench.

The developmental window argument follows from this. The teenage years are when cycle patterns are establishing, when androgen exposure is shaping the long-term phenotype (hirsutism patterns, body composition, insulin-resistance trajectory), and when the foundation of adult cardiometabolic health is being laid. Proponents of earlier intervention argue that addressing insulin resistance and weight during this window may prevent the consolidation of the adult PCOS phenotype and the cardiometabolic comorbidities that follow it. The counterargument is that medication exposure during this same window has unknown long-term consequences, and that adolescents are uniquely vulnerable to medicalization of normal developmental variability.

Both positions are defensible. The evidence base has, until recently, been too thin to resolve them.

The TEAL trial design and results

TEAL was a phase 3 randomized, open-label trial. The investigators enrolled adolescent females with obesity (BMI ≥95th percentile) and a confirmed diagnosis of polycystic ovary syndrome by adolescent-appropriate criteria. Participants were randomized to oral semaglutide or to a standardized lifestyle intervention, and followed at four months for the primary endpoint of percent change in body weight.

The headline result: −5.8% body-weight change in the semaglutide arm versus −1.9% in the lifestyle arm. The difference was statistically significant and clinically meaningful — at the adolescent stage, a 5.8% reduction in body weight in a four-month window is substantial.

Secondary endpoints included insulin and metabolic markers (fasting insulin, HOMA-IR, A1c), androgen profile (total and free testosterone, SHBG, DHEA-S), and cycle data. The trial was not powered for hard reproductive endpoints — those are not the primary outcome of any short-duration adolescent trial — but the metabolic and androgen secondary endpoints moved in the expected direction.

The trial used oral semaglutide rather than the injectable formulations more familiar in adult weight-loss practice. The choice was reasonable: oral semaglutide has been approved in adolescents for the obesity indication, and the oral route reduces some of the administration barriers in the pediatric population. The dose was titrated according to the standard oral semaglutide protocol.

The TEAL paper is posted to SSRN and is being prepared for journal publication. As of the date of this article, it is the largest and most rigorous phase 3 trial of a GLP-1 receptor agonist specifically in the adolescent PCOS population. It is not the only adolescent GLP-1 evidence — liraglutide has been studied in adolescent obesity for several years, and tirzepatide adolescent obesity trials have been published since 2024 — but TEAL is the first to anchor on a PCOS-specific cohort with a PCOS-relevant secondary endpoint set.

The case for early intervention

The argument for treating adolescent PCOS aggressively, when the clinical picture supports it, runs through three points.

First, the developmental window. Insulin resistance that goes untreated through the adolescent and young-adult years has cumulative consequences — the risk of progression to type 2 diabetes by the third or fourth decade is substantially higher in untreated PCOS than in the matched general population. Androgen exposure during the adolescent window shapes long-term body composition, hair distribution patterns, and psychological wellbeing. Early intervention, if it works, prevents the entrenchment of these patterns rather than reversing them later.

Second, the lifestyle ceiling. Lifestyle intervention is the appropriate first-line for adolescent PCOS, and TEAL's lifestyle arm — a structured, supervised intervention — produced a 1.9% weight change at four months. That is real, but it is small, and the four-month result is closer to the realistic ceiling for what supervised lifestyle alone achieves in adolescents with established PCOS-driven metabolic dysfunction. For patients whose clinical trajectory is clearly toward worsening insulin resistance and consolidated PCOS phenotype, medication that augments lifestyle is a defensible addition.

Third, the comparative-risk argument. Untreated PCOS is not benign. The cardiometabolic, mental-health, and fertility consequences of poorly controlled PCOS into the third and fourth decades are substantial. GLP-1 receptor agonists have an accumulating long-term safety profile in adolescents through the obesity indication. The risk of medication exposure is weighed against the risk of no exposure, not against an idealized baseline of perfect health.

The case against early intervention

The counterarguments are also serious.

The long-term safety dataset for chronic GLP-1 exposure starting in adolescence is necessarily thinner than the adult dataset. The medications have been in clinical use long enough to establish a strong adult safety profile, but the question of what happens when therapy begins at 14 or 16 and continues for decades is not yet fully answered.

Adolescents are uniquely vulnerable to weight-related medicalization. The diagnostic boundary between "normal pubertal variation in body composition" and "PCOS-driven obesity requiring medication" is not always crisp, and over-medicalization carries its own psychological and behavioral risks. A teenager prescribed a weight-loss medication is being told something about their body that they will carry forward.

Cycle establishment is part of the issue. Suppressing or modifying cycle patterns during the period when those patterns are physiologically establishing has unclear consequences. Most PCOS therapy is not directly cycle-suppressive in the way hormonal contraception is, but the indirect effect of weight loss and insulin-sensitization on cycle architecture in a still-developing adolescent is not the same as the effect in an adult with a fully consolidated cycle.

These concerns do not invalidate the case for early intervention in the right patient. They calibrate it. The decision is appropriate for some adolescents and not for others, and the clinician's job is to discriminate.

The pregnancy planning conversation across the teen-to-20s window

GLP-1 is contraindicated in pregnancy. The labeling guidance is discontinuation at least eight weeks before a planned pregnancy for semaglutide; four to five weeks for tirzepatide. These washout windows are based on the medications' pharmacokinetics and the absence of adequate human pregnancy safety data.

For adult PCOS patients, the contraception conversation is straightforward — the patient and clinician agree on a method appropriate for the patient's circumstances. For adolescent patients, the conversation is harder.

Contraception decisions for adolescents intersect with parental involvement, with state-level minor-consent law, with the appropriateness of different methods (hormonal vs. barrier, long-acting vs. short-acting), and with the patient's own developmental readiness for the conversation. Many adolescent PCOS patients are already on a combined oral contraceptive for cycle and androgen control, which simplifies the question. Others are not, and the GLP-1 prescribing decision then has to include a contraception decision as a prerequisite.

The TEAL trial handled this with the standard research approach — abstinence or documented contraception throughout the study period — and that is the standard clinical approach as well. The conversation is harder in adolescent care than in adult care, and it has to happen before the medication is prescribed, not after.

How to talk to a clinician about adolescent PCOS prescribing

For families and patients trying to access GLP-1 for adolescent PCOS, the conversation usually starts with the pediatrician or adolescent-medicine specialist who has been managing the case. A few framing points that tend to make the conversation more productive:

• Bring the diagnostic record. Adolescent PCOS diagnoses are sometimes provisional or under-documented in primary-care records. A clear write-up from a pediatric endocrinologist or adolescent-gynecology specialist anchors the conversation in the clinical picture rather than the symptom list.

• Anchor on the trajectory, not just the snapshot. The case for medication in adolescent PCOS is strongest when the trajectory is clearly worsening — insulin markers drifting, weight accumulating despite intervention, cycle patterns becoming more disordered rather than less. A static snapshot of mild symptoms is a weaker case than a documented trajectory.

• Be specific about the lifestyle history. "Tried diet and exercise" is not the same conversation as "completed six months of supervised intervention with documented adherence." TEAL's lifestyle arm was supervised and structured. The argument for adding medication is stronger after a real lifestyle trial.

• Ask about the medication's approved age range. Semaglutide, liraglutide, and tirzepatide are all approved for adolescents 12 and older for the obesity indication. Use in PCOS is off-label, but the medications themselves are within their approved age range. Clinicians sometimes assume that any medication use in adolescents is investigational, and a quick clarification on this point can change the conversation.

• Be ready to talk about contraception. This will come up. Having an answer in advance — even an answer of "I want to discuss the contraception piece with you as part of the prescribing decision" — moves the conversation forward.

The TelePeptide approach

Our standard adult intake age is 18 and older. The vast majority of our PCOS patients fall in this range, and the protocol is calibrated for adult care.

For patients between 16 and 17, we require parent or guardian involvement, a documented PCOS diagnosis from a pediatric or adolescent-medicine specialist, a documented lifestyle-intervention history, and a contraception plan that is appropriate for the patient's circumstances. The clinical-review cadence is tighter than the adult standard — closer follow-up in the first three months of therapy, additional labs at intervals. The clinician makes the final eligibility determination on a case-by-case basis.

We do not treat patients under 16 in any program. The adolescent dataset under 16 is too thin, the developmental considerations are too distinct from the older adolescent picture, and that age group is better served in a pediatric specialty setting.

For patients 18 and over who would have qualified for TEAL or similar adolescent trials — late teenagers and very young adults with established PCOS and obesity — the protocol is the same as our standard adult PCOS protocol: compounded semaglutide at $149/month or compounded tirzepatide at $199/month at the founder rate, clinician-supervised, with the dose calibrated against the metabolic picture rather than against a one-size weight-loss curve.

We do not promise cycle restoration, ovulation, weight outcomes, or any other specific result. We run a clinician-supervised metabolic protocol calibrated against the individual patient and the underlying driver of their PCOS — insulin resistance and weight — and we plan the off-ramp carefully when fertility, life stage, or other circumstances require it.

Compounded medications are prepared by licensed 503A pharmacies and are not FDA-approved.

---

Sources & further reading. The TEAL Study (Morelli, Cree et al., 2025) is posted to SSRN and is being prepared for journal publication; ask your clinician for the current citation. The 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (Teede et al., Monash University) includes a dedicated adolescent section that anchors the conservative diagnostic framework used in adolescent PCOS care. Adolescent obesity prescribing guidance from the AAP and the Endocrine Society is the appropriate companion reading for any prescribing decision in this age group.

This article is for education, not medical advice. Adolescent PCOS prescribing decisions are individualized clinical decisions made by you, the patient, the family, and the prescribing clinician — based on the full clinical picture, the developmental context, and the patient's own goals.